



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DC-0257
Inventors: Buckey et al.
Serial No.: 10/786,429
Filing Date: February 25, 2004
Examiner: Not Yet Assigned
Group Art Unit: 1645
Title: Methods of Preventing or Treating Motion Sickness

I, Kathleen A. Tyrrell, Registration No. 38,350,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: June 9, 2004


Kathleen A. Tyrrell, Registration No. 38,350

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is attached hereto; or
- () Authorization to charge Deposit Account No. 50-1616 the fee of \$180.00 as set forth in §1.17(p) is provided.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- (xx) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(xx) All listed references are in the English language.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: June 9, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 02

Form PTO-1449 Modified		Docket No. DC-0257	Serial No. 10/786,429
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Buckey et al.	
U.S. Department of Commerce		Filing Date February 25, 2004	Group 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Chinn et al., "Evaluation of some Drugs in Seasickness", J. Pharmacology and Experimental Therapeutics 1953 108:69-79
	AB	Chinn et al., "The Effectiveness of Various Drugs for the Prophylaxis of Seasickness", American Journal of Medicine 1952 433-439
	AC	Kohl R.L., "Is there a role for nonsedating antihistamines in motion sickness", J. Respir. Dis. 1991 12:S17-S21
	AD	Wang et al., "Effects of histamine and betahistidine on rat medial vestibular nucleus neurones:possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness", Exp Brain Res 1995 105:18-24
	AE	Wood et al., "Evaluation of Sixteen Anti-motion Sickness Drugs Under Controlled Laboratory Conditions", Aerospace Medicine 1968 1341-1344

EXAMINER	DATE CONSIDERED
----------	-----------------

<p>Form PTO-1449 Modified</p> <p>List of Patents and Publications Cited by Applicant (Use several sheets if necessary)</p> <p>U.S. Department of Commerce</p>	Docket No. DC-0257	Serial No. 10/786,429
	Applicant Buckey et al.	
	Filing Date February 25, 2004	Group 1645

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	NO

EXAMINER

DATE CONSIDERED